However, in lymphoma and renal cell carcinoma, TSP1 was shown to display a clear antiangiogenic effect and TSP1-mimetic drugs are even being considered as potential anti-angiogenic therapeutics [104]. This evidence concerns the gene THBS1 and lymphoma.